- Gilead Sciences (NASDAQ:GILD) Q2 results ($M): Total Revenues: 7,776 (-5.7%); Product Sales: 7,651 (-5.8%).
- Net Income: 3,497 (-22.2%); Non-GAAP Net Income: 4,177 (-13.8%); EPS: 2.58 (-11.6%); Non-GAAP EPS: 3.08 (-2.2%).
- Key Product Sales: Harvoni: 2,564 (-28.9%); Sovaldi: 1,358 (+5.2%); Truvada: 942 (+11.0%); Atripla: 673 (-13.9%); Stribild: 429 (-4.0%); Viread: 287 (+5.9%).
-
2016 Guidance: Net Product Sales: $29.5B - 30.5B from $30.0B - 31.0B; Non-GAAP Gross Margin: 88-90% (unch); Diluted Impact of Certain Items: $1.47-1.53 from $1.10-1.16.
- Shares are down 4% after hours on robust volume.